Incyte Gears Up to Report Q2 Earnings: Is a Beat in the Cards?

Key Takeaways Jakafi sales and stronger royalties from Novartis are expected to have driven top-line growth for INCY.Opzelura sales are likely to have risen on increased patient starts as well as strong EU uptake.Niktimvo launch and Monjuvi's label expansion may have supported incremental revenue contributions.We expect Incyte Corporation (INCY) to surpass expectations when it reports second-quarter 2025 earnings on July 29, before the opening bell. The Zacks Consensus Estimate for the to-be-reported quarte ...